Kayode S Ogungbenro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8352389/publications.pdf

Version: 2024-02-01

69	1,432	377584	425179
papers	citations	21 h-index	34 g-index

69	69	69	2276
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition. AAPS Journal, 2022, 24, 28.	2.2	8
2	Coproporphyrin I as an Endogenous Biomarker to Detect Reduced <scp>OATP1B</scp> Activity and Shift in Elimination Route in Chronic Kidney Disease. Clinical Pharmacology and Therapeutics, 2022, 112, 615-626.	2.3	9
3	Dose individualisation in oncology using chemotherapyâ€induced neutropenia: Example of docetaxel in nonâ€small cell lung cancer patients. British Journal of Clinical Pharmacology, 2021, 87, 2053-2063.	1.1	3
4	Impact of Hepatic CYP3A4 Ontogeny Functions on Drugâ€“Drug Interaction Risk in Pediatric Physiologicallyâ€Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study. Clinical Pharmacology and Therapeutics, 2021, 109, 1618-1630.	2.3	18
5	PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Interâ€Individual Variability. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 137-147.	1.3	21
6	Does â€œBirthâ€•as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Fullâ€Term Neonates by Avoiding the Creatinine Bias. Journal of Clinical Pharmacology, 2021, 61, 159-171.	1.0	25
7	Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 467-477.	1.3	9
8	Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed. European Journal of Pharmaceutical Sciences, 2021, 161, 105781.	1.9	0
9	Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats. Molecular Pharmaceutics, 2021, 18, 2997-3009.	2.3	10
10	Evaluation of area under the concentration curve adjusted by the terminalâ€phase as a metric to reduce the impact of variability in bioequivalence testing. British Journal of Clinical Pharmacology, 2021, , .	1.1	1
11	Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions. European Journal of Pharmaceutical Sciences, 2021, 165, 105932.	1.9	8
12	Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method. AAPS Journal, 2020, 22, 129.	2.2	6
13	Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study. BMJ Open, 2020, 10, e041983.	0.8	14
14	Anakinra in COVID-19: important considerations for clinical trials. Lancet Rheumatology, The, 2020, 2, e379-e381.	2.2	47
15	Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation. Cancer Chemotherapy and Pharmacology, 2020, 85, 817-825.	1.1	2
16	Development and validation of a methotrexate adherence assay. Annals of the Rheumatic Diseases, 2019, 78, 1192-1197.	0.5	13
17	An evaluation of cetuximab dosing strategies using pharmacokinetics and cost analysis. Journal of Pharmacy and Pharmacology, 2019, 71, 1222-1230.	1.2	2
18	A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents. European Journal of Clinical Pharmacology, 2019, 75, 1227-1235.	0.8	5

#	Article	IF	Citations
19	A study of the dosage and duration for levobupivacaine infusion by the caudalâ€epidural route in infants aged 3â€6 months. Paediatric Anaesthesia, 2019, 29, 161-168.	0.6	8
20	Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 125-135.	1.3	36
21	Reduction of inflammation after administration of interleukin-1 receptor antagonist following aneurysmal subarachnoid hemorrhage: results of the Subcutaneous Interleukin-1Ra in SAH (SCIL-SAH) study. Journal of Neurosurgery, 2018, 128, 515-523.	0.9	83
22	Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis. Clinical Pharmacology and Therapeutics, 2018, 103, 582-590.	2.3	51
23	Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. Journal of Clinical Pharmacology, 2017, 57, 1554-1563.	1.0	16
24	The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine. Journal of Critical Care, 2017, 40, 113-118.	1.0	7
25	Choosing an optimal input for an intravenous glucose tolerance test to aid parameter identification. Journal of Pharmacy and Pharmacology, 2017, 69, 1275-1283.	1.2	1
26	Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data. Cancer Chemotherapy and Pharmacology, 2016, 77, 927-938.	1.1	10
27	Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data. AAPS Journal, 2016, 18, 196-209.	2.2	19
28	Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 1-12.	0.8	16
29	Physiologically based pharmacokinetic model for 6â€mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity. British Journal of Clinical Pharmacology, 2015, 80, 86-100.	1.1	20
30	Methods and software tools for design evaluation in population pharmacokineticsâ€“pharmacodynamics studies. British Journal of Clinical Pharmacology, 2015, 79, 6-17.	1.1	65
31	A Physiologically Based Pharmacokinetic Model for Clobazam and Stiripentol in Adults and Children. Pharmaceutical Research, 2015, 32, 144-157.	1.7	13
32	Model-Based Evaluation of the Impact of Formulation and Food Intake on the Complex Oral Absorption of Mavoglurant in Healthy Subjects. Pharmaceutical Research, 2015, 32, 1764-1778.	1.7	18
33	Empirical and Semi-Mechanistic Modelling of Double-Peaked Pharmacokinetic Profile Phenomenon Due to Gastric Emptying. AAPS Journal, 2015, 17, 227-236.	2.2	24
34	Model of mucociliary clearance in cystic fibrosis lungs. Journal of Theoretical Biology, 2015, 372, 81-88.	0.8	29
35	Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 639-657.	0.8	18
36	Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: Which measure of variability should be used?. Journal of Clinical Pharmacology, 2014, 54, 311-317.	1.0	3

#	Article	IF	Citations
37	A methodological framework for drug development in rare diseases. Orphanet Journal of Rare Diseases, 2014, 9, 164.	1.2	21
38	A physiologically based pharmacokinetic model for Valproic acid in adults and children. European Journal of Pharmaceutical Sciences, 2014, 63, 45-52.	1.9	27
39	Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 159-171.	0.8	22
40	Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 173-185.	0.8	19
41	Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet Journal of Rare Diseases, 2013, 8, 48.	1.2	83
42	The population pharmacokinetics of Râ€•and Sâ€warfarin: effect of genetic and clinical factors. British Journal of Clinical Pharmacology, 2012, 73, 66-76.	1.1	70
43	A semi-mechanistic gastric emptying pharmacokinetic model for 13C-octanoic acid: An evaluation using simulation. European Journal of Pharmaceutical Sciences, 2012, 45, 302-310.	1.9	6
44	Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 681-695.	1.5	9
45	Intravenous Anakinra can Achieve Experimentally Effective Concentrations in the Central Nervous System within a Therapeutic Time Window: Results of a Dose-Ranging Study. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 439-447.	2.4	92
46	Structural identifiability analysis of pharmacokinetic models using DAISY: semi-mechanistic gastric emptying models for 13C-octanoic acid. Journal of Pharmacokinetics and Pharmacodynamics, 2011, 38, 279-292.	0.8	4
47	Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments. Journal of Pharmacokinetics and Pharmacodynamics, 2011, 38, 449-469.	0.8	13
48	A Semi-mechanistic Gastric Emptying Model for the Population Pharmacokinetic Analysis of Orally Administered Acetaminophen in Critically Ill Patients. Pharmaceutical Research, 2011, 28, 394-404.	1.7	8
49	Sample size/power calculations for repeated ordinal measurements in population pharmacodynamic experiments. Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37, 67-83.	0.8	9
50	Sample-size calculations for multi-group comparison in population pharmacokinetic experiments. Pharmaceutical Statistics, 2010, 9, 255-268.	0.7	7
51	Optimal Design of Pharmacokinetic Studies. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 250-255.	1.2	52
52	Sample Size/Power Calculations for Population Pharmacodynamic Experiments Involving Repeated-Count Measurements. Journal of Biopharmaceutical Statistics, 2010, 20, 1026-1042.	0.4	19
53	Application of optimal design methodologies in clinical pharmacology experiments. Pharmaceutical Statistics, 2009, 8, 239-252.	0.7	25
54	Population pharmacokinetics and optimal design of paediatric studies for famciclovir. British Journal of Clinical Pharmacology, 2009, 68, 546-560.	1.1	23

#	Article	IF	Citations
55	An Effective Approach for Obtaining Optimal Sampling Windows for Population Pharmacokinetic Experiments. Journal of Biopharmaceutical Statistics, 2009, 19, 174-189.	0.4	13
56	Optimisation of sampling windows design for population pharmacokinetic experiments. Journal of Pharmacokinetics and Pharmacodynamics, 2008, 35, 465-482.	0.8	9
57	Drugâ€“drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes. Journal of Pharmacokinetics and Pharmacodynamics, 2008, 35, 635-659.	0.8	27
58	Drugâ€“drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results. Journal of Pharmacokinetics and Pharmacodynamics, 2008, 35, 661-681.	0.8	13
59	How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach. European Journal of Clinical Pharmacology, 2008, 64, 705-713.	0.8	30
60	Incorporating Correlation in Interindividual Variability for the Optimal Design of Multiresponse Pharmacokinetic Experiments. Journal of Biopharmaceutical Statistics, 2008, 18, 342-358.	0.4	9
61	Sample Size Calculations for Population Pharmacodynamic Experiments Involving Repeated Dichotomous Observations. Journal of Biopharmaceutical Statistics, 2008, 18, 1212-1227.	0.4	5
62	Design of population pharmacokinetic experiments using prior information. Xenobiotica, 2007, 37, 1311-1330.	0.5	5
63	Design of population pharmacokinetic experiments using prior information. Xenobiotica, 2007, 37, 1311-1330.	0.5	9
64	A program for individual and population optimal design for univariate and multivariate response pharmacokineticâ€“pharmacodynamic models. Computer Methods and Programs in Biomedicine, 2007, 86, 51-61.	2.6	40
65	Optimal Design for Multiresponse Pharmacokineticâ€“Pharmacodynamic Models â€“ Dealing with Unbalanced Designs. Journal of Pharmacokinetics and Pharmacodynamics, 2007, 34, 313-331.	0.8	17
66	Sample Size Calculations Based on Generalized Estimating Equations for Population Pharmacokinetic Experiments. Journal of Biopharmaceutical Statistics, 2006, 16, 135-150.	0.4	22
67	Optimal Design for Multivariate Response Pharmacokinetic Models. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33, 97-124.	0.8	47
68	The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments. Computer Methods and Programs in Biomedicine, 2005, 80, 115-125.	2.6	27
69	Optimal Blood Sampling Time Windows for Parameter Estimation Using a Population Approach: Design of a Phase II Clinical Trial. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 737-756.	0.8	12